Increasing genetic referral and expanded testing resulted in higher estimated rates of risk-reducing surgery (Figure 3) and lower incidence of breast and ovarian cancer in relatives of probands with a P/LP variant in BRCA1, BRCA2 or PALB2 (Figure 4). The gene discussed is PALB2; the disease is ovarian carcinoma.